Aspirin Inhibits MMP-2 and MMP-9 Expressions and Activities through Upregulation of PPAR<symbol unicode="03B1" ascii="alpha"></symbol>/<symbol unicode="03B3" ascii="gamma"></symbol> and TIMP Gene Expressions in ox-LDL-Stimulated Macrophages Derived from Human Monocytes
Yinan Hua,Jie Xue,Fan Sun,Lujia Zhu,Meilin Xie
DOI: https://doi.org/10.1159/000166183
IF: 3.4293
2008-01-01
Pharmacology
Abstract:Recently, aspirin has been shown to alleviate matrix metalloproteinase (MMP) expression, but the underlying mechanism is still unclear. In this study, the effects of aspirin on oxidative low-density lipoprotein (ox-LDL)-stimulated human monocyte-derived macrophages were examined. Following treatment of cells with aspirin, MMP-2 and MMP-9 expression and release were significantly reduced. Moreover, expression of peroxisome proliferator-activated receptors (PPARs) and was markedly enhanced. The effect of PPAR inhibitors on MMP levels in aspirin-treated cells was examined. RT-PCR and ELISA assays showed that inhibition of MMP-9 levels by aspirin was notably alleviated by PPAR antagonists. Interestingly, expression of nuclear factor (NF)B was also decreased by aspirin. RT-PCR study also indicated that aspirin could upregulate the expression of tissue inhibitors of metalloproteinases (TIMP)-1 and TIMP-2. In all of these studies, lower dosage (50 or 100 g/ml) exerted the best effect. These results demonstrate that aspirin could inhibit MMP-2 and MMP-9 expression through upregulation of Received: May 9, 2008 Accepted after revision: July 24, 2008 Published online: October 30, 2008 Prof. Meilin Xie Department of Pharmacology Soochow University Suzhou 215123 (China) Tel. +86 512 6588 0320, Fax +86 512 6588 0130, E-Mail xiemeilin@suda.edu.cn © 2008 S. Karger AG, Basel 0031–7012/09/0831–0018$26.00/0 Accessible online at: www.karger.com/pha Aspirin Inhibits MMP-2 and MMP-9 Expressions in Human Macrophages Pharmacology 2009;83:18–25 19 shoulder regions [3] , and they might promote weakening of fibrous caps and subsequent disrupture of atherosclerotic plaques. As a result, MMPs derived from macrophages are important to plaque rupture. MMP-2 and MMP-9, two of them, are considered significant to plaque instability [4, 5] . Tissue inhibitors of metalloproteinases (TIMPs) are a family of naturally occurring specific inhibitors that block activation of both soluble MMPs and pro-MMPs [6] . The proteolytic activities of proinflammatory MMPs and their inhibitors, TIMPs, regulate the physiological remodeling of the extracellular matrix. The proteolytic activities of MMPs are counterbalanced by at least four TIMPs, namely, TIMP-1 to TIMP-4 [7] . MMPs and TIMPs, which are synthesized and secreted by macrophages and smooth muscle cells in atherosclerotic lesions, mainly contribute to the inflammatory state and the extracellular remodeling that occurs during key steps in atherogenesis and vascular remodeling [1] . Peroxisome proliferator-activated receptors (PPARs) are ligand-activated nuclear transcription factors that play important roles in glucose and lipid homeostasis, cell proliferation, differentiation and apoptosis [8] . It has also been demonstrated that PPAR may play a role in the control of inflammatory response, and recruitment and adhesion of leukocytes and monocytes to atherosclerotic lesions [9] . Recent studies have demonstrated that PPAR and PPAR could be present in macrophages derived from human monocytes [10] , and their agonists could markedly downregulate the secretion of MMP-9, with nuclear factor (NF)B playing an important role in the process [11] . Similarly, another clinical study showed that treatment of type 2 diabetes patients with PPAR activator rosiglitazone could significantly reduce MMP-9 serum level [12] . Aspirin (acetylsalicylic acid) has been used for the secondary prevention of cardiocerebrovascular diseases for many years, and could decrease the evolution of vascular events by 20–25% in patients with varieties of vascular diseases [13] . Recent studies revealed that aspirin could enhance CD36, SR-BI and ABCA1 expressions in human macrophages in vitro [14, 15] , suggesting that the drug could improve the lipid metabolism of macrophages. Aspirin was found to be able to attenuate MMP expression in tumor cells and human coronary endothelial cells in vitro [16, 17] , but it had no significant effect on monocyte MMP-9 expression in diabetics [18] . In the present study, we wanted to illustrate whether aspirin could alleviate MMP-2 and MMP-9 mRNA expressions and releases in human monocyte-derived macrophages, and whether PPAR / and NFB were involved in the process of regulation. Also, the influence of aspirin on the levels of TIMPs, the inhibitors of MMPs, was investigated. Besides, the aspirin concentration exerting the best effect was determined as well. Materials and Methods Cells and Reagents The cell line THP-1 was purchased from the Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences. Aspirin was a product of Sigma-Aldrich Chemical (St. Louis, Mo., USA). MK886 (PPAR inhibitor) was purchased from Cayman Chemical Company (Ann Arbor, Mich., USA). GW9662 (PPAR inhibitor) was purchased from Alexis Biochemicals Corporation (Lausen, Switzerland). Cell Culture The human monocytic cell line THP-1 was cultured in RPMI1640 (Gibco BRL) supplemented with L -glutamine (Gibco BRL) and 10% fetal bovine serum (Gibco BRL). Cells were maintained at 37 ° C in a humidified atmosphere with 5% CO 2 . Experimental Design THP-1 cells were firstly cultured in RPMI-1640 medium containing 100 ng/ml phorbol 12-myristate 13-acetate (Alexis Corporation, San Diego, Calif., USA) for 24 h following differentiation to macrophages. They were then allocated equally into six culture flasks. Forty-eight hours later, cells were washed in PBS and kept in RPMI-1640 medium with 80 g/ml oxidative lowdensity lipoprotein (ox-LDL; Peking Union Medical College, China) for 24 h. Then, the cells were divided into six groups and incubated with either RPMI-1640, or RPMI-1640 plus 12.5, 25, 50, 100 or 200 g/ml aspirin, respectively. For the other study, the ox-LDL-stimulated macrophages were pretreated with or without 4 mol/l MK886 (PPAR inhibitor) and/or 20 mol/l GW9662 (PPAR inhibitor) for 2 h before incubation with aspirin 50 g/ ml. These cultured cells and supernatants were then collected for measurement of the following design parameters after treatment with aspirin for 24 h. Total RNA Extraction After the cells were treated with aspirin for 24 h, they were used to extract total RNA by the following method. One milliliter of trizol (Invitrogen Corporation, USA) was added after removal of the culture medium. Cell lysate was passed through a pipette, and then shifted into a 1.5-ml polypropylene tube. Chloroform (0.2 ml) was added and the homogenate was centrifuged at 12,000 g for 15 min at 4 ° C after violently shaking it for 3 min at room temperature. The aqueous phase was transferred to a fresh tube and mixed with 0.5 ml isopropyl alcohol followed by incubation at room temperature for 10 min. The suspension was centrifuged at 10,000 g for 10 min at 4 ° C. The pellet was washed by 1 ml of 75% ethanol. Then the mixture was vortexed and centrifuged at 7,500 g for 5 min at 4 ° C. The consequent pellet was dried at room temperature and redissolved in 0.1% DEPC solution. Samples were stored at –80 ° C for RT-PCR.